HealthEquity, Inc
HQY
$97.67
-1.03%
HealthEquity, Inc is a leading provider of technology-enabled services and payment solutions for healthcare savings and spending accounts, primarily managing Health Savings Accounts (HSAs) and other consumer-directed benefits for employers. As the largest dedicated HSA custodian in the United States, the company differentiates itself through its integrated platform that combines account administration, payment processing, and investment advisory services. The current investor narrative centers on the company's accelerating revenue growth driven by rising HSA adoption and higher interest income, while margin expansion and strong free cash flow generation have bolstered confidence in its scalable business model. Recent analyst upgrades and a robust earnings report have shifted focus toward the company's ability to sustain double-digit growth in a favorable regulatory environment.…
HQY
HealthEquity, Inc
$97.67
Investment Opinion: Should I buy HQY Today?
Rating: Buy. HealthEquity offers a compelling risk-reward with accelerating revenue growth, expanding margins, and a forward P/E at a discount to peers. The consensus Strong Buy rating and average target of $117.40 support this view.
Supporting Evidence: Revenue growth reaccelerated to 7.2% YoY in Q1 2026, gross margin expanded to 72.3% from 62.4%, operating margin improved to 29.0%, and TTM free cash flow of $487.6M yields 6.6%. The forward P/E of 17.9x is below the industry average of 22.0x, and the PEG ratio of 0.27x suggests undervaluation relative to growth.
Risks & Conditions: The biggest risks are interest rate sensitivity (financial service revenue growth could slow) and the trailing P/E premium (34.3x vs. industry 22.0x). This Buy would be downgraded to Hold if revenue growth decelerates below 5% or if gross margins fall below 65%. Upgrade to Strong Buy if forward P/E compresses below 15x or if revenue growth exceeds 10%. Overall, the stock appears fairly valued to slightly undervalued on a forward basis, but overvalued on trailing metrics.
Sign up to view all
HQY 12-Month Price Forecast
HealthEquity's improving fundamentals and attractive forward valuation support a bullish stance, but the trailing P/E premium and interest rate sensitivity warrant medium confidence. The base case of 6-8% revenue growth and margin expansion is most likely, with upside if growth accelerates. Key monitoring points include Q2 2026 earnings and Fed policy signals. A downgrade to neutral would occur if revenue growth falls below 5% or margins contract.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on HealthEquity, Inc's 12-month outlook, with a consensus price target around $117.40 and implied upside of +20.2% versus the current price.
Average Target
$117.40
0 analysts
Implied Upside
+20.2%
vs. current price
Analyst Count
—
covering this stock
Price Range
$105 - $135
Analyst target range
HealthEquity is covered by 15 analysts, with a consensus recommendation of 'Strong Buy' (mean rating of 1.33 on a 1-5 scale). The average price target is $117.40, implying 20.2% upside from the current price of $97.67. The distribution shows no sell ratings, with the majority of analysts rating the stock as a buy or outperform. This bullish consensus reflects confidence in the company's growth trajectory and margin expansion. The target price range spans from $105.00 (low) to $135.00 (high), representing a 28.6% spread from low to high. The high target of $135 assumes continued revenue acceleration and margin expansion, potentially driven by higher interest rates and HSA adoption. The low target of $105 implies a more conservative scenario with slower growth or margin compression. Recent analyst actions have been uniformly positive, with upgrades from BMO Capital (Market Perform to Outperform in April 2026) and reiterated Outperform ratings from RBC Capital and Barrington Research. The wide target spread indicates moderate uncertainty, but the consistent upgrade momentum suggests analysts see a favorable risk-reward profile.
Bulls vs Bears: HQY Investment Factors
HealthEquity presents a compelling bull case driven by accelerating revenue growth, expanding margins, and strong free cash flow, with a forward P/E at a discount to peers. However, the trailing P/E premium and sensitivity to interest rates introduce risk. The bull case currently has stronger evidence, supported by analyst upgrades and improving fundamentals. The central tension is whether the company can sustain its growth reacceleration and margin expansion in a potentially lower interest rate environment, which would determine if the forward P/E discount is justified or if the stock faces multiple compression.
Bullish
- Revenue Growth Reaccelerating: Revenue grew 7.2% YoY in Q1 2026 to $354.6M, accelerating from 3.8% in Q4 2025, driven by a 10.5% increase in financial service revenue and 7.2% service revenue growth. This reacceleration signals strong HSA adoption and account utilization.
- Significant Margin Expansion: Gross margin expanded to 72.3% in Q1 2026 from 62.4% a year ago, while operating margin improved to 29.0% from 20.1%. Net margin rose to 19.6% from 14.9%, demonstrating strong operating leverage.
- Robust Free Cash Flow Generation: TTM free cash flow stands at $487.6M, yielding a 6.6% FCF yield on the current market cap. This cash generation supports organic growth and reduces reliance on external financing.
- Attractive Forward Valuation: Forward P/E of 17.9x is at a 19% discount to the industry average of 22.0x, while the PEG ratio of 0.27x suggests undervaluation relative to expected growth. The trailing P/E of 34.3x is near the low end of its 5-year range.
Bearish
- High Trailing P/E Premium: Trailing P/E of 34.3x is 56% above the industry average of 22.0x, indicating the stock is priced for perfection. Any earnings miss could trigger multiple compression.
- Interest Income Sensitivity: Financial service revenue, which grew 10.5% YoY, is sensitive to interest rate changes. A decline in rates could pressure this key growth driver, as HSA custodial balances earn interest income.
- Low Beta Limits Upside in Bull Markets: With a beta of 0.21, the stock offers downside protection but may underperform in strong market rallies. The 1-year relative strength of -20.8% vs. the S&P 500 highlights this lag.
- Regulatory and Competitive Risks: Changes to HSA contribution limits or healthcare policy could impact adoption. Competition from larger financial institutions and fintech disruptors may pressure margins and market share.
HQY Technical Analysis
HealthEquity's stock is in a strong uptrend, with the price surging 13.5% over the past three months and 14.4% over the past six months, though it remains 2.4% lower year-over-year. The current price of $97.67 sits at 92.2% of its 52-week range ($72.76 to $105.96), indicating the stock is near the upper end of its range and reflecting bullish momentum. This positioning near highs suggests strong investor conviction but also carries risk of overextension, as the stock has rallied sharply from its February lows. Short-term momentum is accelerating, with the 1-month price change of +13.1% outpacing the 3-month change of +13.5%, signaling building buying pressure. The stock's relative strength versus the S&P 500 is also positive, with a 1-month relative strength of +12.8%, indicating outperformance. However, the 1-year relative strength of -20.8% shows that the stock has lagged the broader market over the longer term, suggesting the recent rally may be a catch-up move. The 52-week low of $72.76 provides a key support level, while the 52-week high of $105.96 acts as immediate resistance. A breakout above $105.96 would signal a new uptrend leg, potentially targeting analyst high estimates of $135. Conversely, a breakdown below $72.76 could indicate a bearish reversal. With a beta of 0.21, HealthEquity is significantly less volatile than the market, meaning it offers downside protection but may underperform in strong bull markets.
Beta
0.21
0.21x market volatility
Max Drawdown
-30.6%
Largest decline past year
52-Week Range
$73-$106
Price range past year
Annual Return
-2.4%
Cumulative gain past year
| Period | HQY Return | S&P 500 |
|---|---|---|
| 1m | +13.1% | -0.5% |
| 3m | +13.5% | +4.9% |
| 6m | +14.4% | +9.7% |
| 1y | -2.4% | +18.4% |
| ytd | +7.2% | +9.0% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
HQY Fundamental Analysis
HealthEquity's revenue trajectory is accelerating, with the most recent quarter (April 2026) reporting revenue of $354.6 million, up 7.2% year-over-year. This growth is driven by a 7.2% increase in service revenue ($122.9 million) and a 10.5% rise in financial service revenue ($174.3 million), while credit and debit card fees grew 8.5% to $57.4 million. The multi-quarter trend shows revenue growth improving from 3.8% in Q4 2025 to 7.2% in Q1 2026, indicating a reacceleration. This growth trajectory supports the investment case as it reflects higher HSA adoption and increased account utilization. Profitability is robust, with net income of $69.4 million in the latest quarter, representing a net margin of 19.6%, up from 14.9% in the prior quarter. Gross margin expanded to 72.3% from 62.4% a year ago, driven by a favorable mix shift toward higher-margin service revenue. Operating margin improved to 29.0% from 20.1% in the previous quarter, reflecting operating leverage. The company is consistently profitable, with EPS of $0.82 in Q1 2026, up from $0.62 in the year-ago period. HealthEquity maintains a strong balance sheet with a debt-to-equity ratio of 0.48 and a current ratio of 3.27, indicating ample liquidity. Free cash flow generation is robust, with TTM free cash flow of $487.6 million, yielding a FCF yield of 6.6% based on the current market cap. The company's ROE of 10.2% and ROA of 6.5% demonstrate efficient capital allocation, while its ability to generate positive free cash flow consistently reduces reliance on external financing.
Quarterly Revenue
$354641000.0B
2026-04
Revenue YoY Growth
+7.2%
YoY Comparison
Gross Margin
72.3%
Latest Quarter
Free Cash Flow
$487637000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is HQY Overvalued?
Given HealthEquity's positive net income, the primary valuation metric is the P/E ratio. The trailing P/E stands at 34.3x, while the forward P/E is 17.9x, implying the market expects significant earnings growth. The gap between trailing and forward P/E suggests analysts anticipate EPS to nearly double over the next year, driven by margin expansion and revenue growth. Compared to the industry average P/E of 22.0x (based on the Medical - Healthcare Information Services sector), HealthEquity trades at a 56% premium on a trailing basis. However, on a forward basis, the P/E of 17.9x is at a 19% discount to the industry forward average of 22.0x, indicating that the market is pricing in above-average growth. The PEG ratio of 0.27x suggests the stock is undervalued relative to its growth rate, as a PEG below 1.0 typically indicates undervaluation. Historically, HealthEquity's trailing P/E has ranged from 25x to 325x over the past five years, with the current 34.3x near the lower end of that range. This suggests the stock is not excessively expensive by its own historical standards, especially considering the recent earnings acceleration. The P/S ratio of 5.6x is below the historical average of 22x, further supporting the view that valuation is reasonable relative to sales growth.
PE
34.3x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 25x~142x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
16.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: HealthEquity's debt-to-equity ratio of 0.48 is manageable, but interest expense of $12.6M in Q1 2026 (3.5% of revenue) could pressure margins if rates rise. The company's revenue growth is dependent on HSA adoption and account utilization; a slowdown in either could impair the growth story. Free cash flow of $487.6M TTM is robust, but any deterioration in cash conversion could raise concerns given the 34.3x trailing P/E. Margin expansion is a key driver, and gross margin of 72.3% may face pressure from competitive pricing or mix shifts.
Market & Competitive Risks: The stock's trailing P/E of 34.3x is a 56% premium to the industry, making it vulnerable to valuation compression if growth disappoints. With a beta of 0.21, the stock is less correlated to the market, but its 1-year relative strength of -20.8% indicates it has lagged the S&P 500 significantly. Competition from banks and fintech firms offering HSA services could erode market share. Regulatory changes, such as modifications to HSA rules or tax advantages, pose a tail risk.
Worst-Case Scenario: A combination of slowing revenue growth (e.g., below 5%), margin compression from competitive pressure, and a declining interest rate environment could cause the stock to re-rate lower. The 52-week low of $72.76 represents a 25.5% downside from the current price of $97.67. In a severe scenario, the stock could test the low target of $105 (only 7.5% downside) or even the 52-week low, implying a potential loss of up to 25.5%.
FAQ
The primary risks are: 1) Interest rate sensitivity – financial service revenue (10.5% YoY growth) could decline if the Fed cuts rates. 2) Valuation risk – trailing P/E of 34.3x leaves little room for error; an earnings miss could trigger multiple compression. 3) Competitive risk – larger financial institutions and fintechs could pressure margins and market share. 4) Regulatory risk – changes to HSA rules or tax advantages could slow adoption. The most severe risk is a combination of rate cuts and growth deceleration, which could drive the stock to the 52-week low of $72.76, a 25.5% downside.
Analysts forecast a 12-month price range of $105 to $135, with an average target of $117.40 (20.2% upside). The base case (55% probability) assumes 6-8% revenue growth and margin expansion, targeting $105-$117.40. The bull case (25% probability) sees double-digit growth driving the stock to $117.40-$135. The bear case (20% probability) involves growth deceleration and margin pressure, with a target of $72.76-$105. The most likely scenario is the base case, supported by current revenue acceleration and strong free cash flow.
On a trailing basis, HQY's P/E of 34.3x is 56% above the industry average of 22.0x, suggesting overvaluation. However, on a forward basis, the P/E of 17.9x is at a 19% discount to the industry, indicating the market expects significant earnings growth. The PEG ratio of 0.27x (well below 1.0) supports the view that the stock is undervalued relative to its growth rate. Historically, the trailing P/E has ranged from 25x to 325x over five years, and the current 34.3x is near the lower end, implying reasonable valuation by its own history. Overall, the stock appears fairly valued to slightly undervalued on forward metrics but expensive on trailing earnings.
HealthEquity presents a favorable risk-reward for growth-oriented investors. The stock has a consensus Strong Buy rating with an average target price of $117.40, implying 20.2% upside from $97.67. The forward P/E of 17.9x is below the industry average of 22.0x, and the PEG ratio of 0.27x suggests undervaluation relative to expected earnings growth. However, the trailing P/E of 34.3x is elevated, and the stock is sensitive to interest rates. It is a good buy for those with a 12-month horizon who believe revenue growth can sustain above 7% and margins continue to expand. Conservative investors may prefer to wait for a pullback closer to the 52-week low of $72.76.
HealthEquity is best suited for a medium- to long-term investment horizon of 12-24 months. The stock's low beta of 0.21 provides downside protection but limits short-term trading gains. The company pays no dividend, so returns rely on capital appreciation driven by earnings growth. With revenue accelerating and margins expanding, the stock offers compounding potential for long-term holders. Short-term traders may find the stock less volatile, but the 13.1% one-month gain suggests recent momentum. A minimum holding period of 12 months is recommended to allow the growth story to play out and reduce the impact of short-term fluctuations.